Figure 4.

Combination therapies significantly improves outcome in a SUIT‐2 orthotopic pancreatic cancer model. (a, b) Representative images of mice in each group obtained by in vivo imaging. (c, d) Box plots of bioluminescent intensities of tumors in mice of gemcitabine (Gem)‐ and TS‐1‐treated groups at day 20 and 16, respectively, which were the last days that all mice in the control groups were still alive. *P < 0.05, **P < 0.01, ***P < 0.001. (e, f) Body weight of mice in gemcitabine‐ and TS‐1‐treated groups. No significant difference was observed between any groups.